EMA Reviews Samsung Bioepis’ Lucentis Biosimilar For Eye Diseases

Published date07 October 2020
Subject MatterEU,Prescription Drugs,Biosimilars,Pharmaceutical Industry,Samsung Bioepis,European Medicines Agency (EMA),Marketing Authorization Application
Law FirmGoodwin

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT